Arrêt de la chambre de justice contre J. Lempereur, subdélégué en titre d'office de la ville et élection de Montdidier, par lequel il est condamné aux galères pour neuf ans, en 60000 livres d'amende ; et le nommé Adrien Buquet, son préposé, banni du ressort du parlement

[Acte. 1716-10-08. Paris]

Arrêt de la chambre de justice qui met les plaignants, dénonciateurs et témoins sous la protection sauvegarde du roi et de la chambre, et porte peine de mort contre ceux qui les intimideront

[Acte. 1716-10-20]

Arrêt de la chambre de justice contre Jean-François Gruet, huissier à cheval au Châtelet de Paris, préposé au recouvrement des débets de la capitation des communautés de Paris, condamné aux galères à perpétuité avec confiscation de ses biens, 20000 livres pour être distribuées aux pauvres desdites communautés

[Acte. 1716-12-07]

Arrêt de la chambre de justice contre ceux qui recèlent les effets des accusés qui ont été condamnés

[Acte. 1717-01-07]

Arrêt de la chambre de justice contre Jean-François Liévain, ci-devant notaire et receveur général de plusieurs loteries, par lequel il est condamné au bannissement pour cinq ans du ressort du parlement

[Acte. 1717-02-12]

Arrest de la chambre de justice contre les assemblées faites par les intéressez dans les affaires du Roy. Du 26 may 1716...

[Acte. 1716-05-26]

Severe and prolonged hypophosphatemia after intravenous iron administration in a malnourished patient.

Malnutrition may result in a phosphate-deficient state owing to a chronically insufficient phosphate intake. Concomitant iron deficiency is common and often supplemented by the intravenous route. It is not widely recognized that some parenteral iron formulations can induce hypophosphatemia. Herein we report a case of a severe and symptomatic hypophosphatemia (0.18 mM, normal range 0.8-1.4 mM) associated with an inappropriately reduced tubular reabsorption of phosphate (33%, norm >95%) in a malnourished patient with anorexia/bulimia who received 2 × 500 mg iron carboxymaltose (FCM) intravenously. Despite intravenous and oral phosphate supplements, it required 2 months to achieve a normal serum phosphate level. Our case demonstrates that in a chronically malnourished and phosphate-deficient state intravenous FCM could potentially be dangerous. If this form of iron application cannot be avoided, phosphate supplementation before and after iron infusion as well as close monitoring of phosphate levels are needed.

DuP 532, an angiotensin II receptor antagonist: first administration and comparison with losartan.

We investigated the tolerability and angiotensin II antagonist activity of oral DuP 532 in healthy male subjects. DuP 532 (1 to 200 mg) was well tolerated, with no effect on blood pressure or heart rate. Compared with losartan (100 mg), DuP 532 (200 mg) was a weak antagonist of pressor responses to intravenous angiotensin II. Maximum inhibition of diastolic pressor response was 86% (95% confidence interval [CI], 84%, 88%) approximately 4.6 hours after losartan and 48% (95% CI, 38%, 56%) 8.7 hours after DuP 532. Twenty-four hours after dosing, inhibition by losartan and DuP 532 was similar (40% to 45%). DUP 532 is extensively bound in human plasma, with an in vitro free fraction of 0.06. Although DuP 532 and EXP3174 (losartan's active metabolite) have similar AT1-receptor potency, and plasma concentrations of DuP 532 were much greater than losartan/EXP3174, the level of antagonism was much less for DuP 532. These results indicate that multiple factors determine the in vivo potency of angiotensin II antagonists, including affinity for and distribution to the receptor as modulated by plasma binding.

Report on a review of selected general and application controls over the University of Northern Iowa Facility Administration and Maintenance Information System for the period April 29, 2014 through June 5, 2014

Report on a review of selected general and application controls over the University of Northern Iowa Facility Administration and Maintenance Information System for the period April 29, 2014 through June 5, 2014

Report on the Iowa Department of Justice for the year ended June 30, 2014

Report on the Iowa Department of Justice for the year ended June 30, 2014

In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

The present study evaluates the potential of third-generation lentivirus vectors with respect to their use as in vivo-administered T cell vaccines. We demonstrate that lentivector injection into the footpad of mice transduces DCs that appear in the draining lymph node and in the spleen. In addition, a lentivector vaccine bearing a T cell antigen induced very strong systemic antigen-specific cytotoxic T lymphocyte (CTL) responses in mice. Comparative vaccination performed in two different antigen models demonstrated that in vivo administration of lentivector was superior to transfer of transduced DCs or peptide/adjuvant vaccination in terms of both amplitude and longevity of the CTL response. Our data suggest that a decisive factor for efficient T cell priming by lentivector might be the targeting of DCs in situ and their subsequent migration to secondary lymphoid organs. The combination of performance, ease of application, and absence of pre-existing immunity in humans make lentivector-based vaccines an attractive candidate for cancer immunotherapy.